E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pain during eye examination of premature infants. |
|
E.1.1.1 | Medical condition in easily understood language |
Pain during eye examination of premature infants. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to investigate whether clonidine works is a good analgesic during examination for Retinopathy of Prematurity (ROP). |
|
E.2.2 | Secondary objectives of the trial |
- Change in emotional sweating Galvanic Skin Response (GSR). - Evaluation of the safety of Clonidine in regards to AEs, SAEs and SUSARs. - Will the infant be easier to examine by the eye doctor after receiving Clonidine? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• The infant is admitted to the study clinic • The infants guardian/s has/have given their written consent to the child's participation in the study. • The infant is born before gestation week 30
|
|
E.4 | Principal exclusion criteria |
• Children who has received beta blockers, pain reliever or sedating drug within 24 hours of eye examination. • Previously documented kidney failure • Does not have a gastric tube • Neurologically affected • Known cardiac arrhythmia • Circulatory instability (defined as mean arterial pressure lower than the child's gestational age)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
PIPP-R scores within 30 seconds after the eye examination has been initiated, i.e. when the hooks are in place in the first eye in Uppsala or when the first eye is held open in Örebro. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation during the two eye examinations. |
|
E.5.2 | Secondary end point(s) |
- GSR: Area small peaks, area huge peaks, peaks per second och average rise time. - Number of reported AEs, SAEs and SUSARS - A VAS scale of 0-10 cm, from very easy to examin (0) to very difficult to examin (10) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- GSR: values are collected within the first 30 seconds of the examination. - AEs, SAEs are collected within 72 hours from the examination. - VAS evaluation after the two eye examinations. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |